WSTAM
CTIC

Wilbanks Smith & Thomas Asset Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-500
Closed -$1K – 1577
2018
Q3 		$1K Buy
+500
New +$1.24K ﹤0.01% 1599

Other funds holding CTIC

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's CTIC Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q4 2018, closing a stake of 500 shares — an estimated $1K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in CTIC in Q3 2018 and held it in 1 quarter. The position peaked at $1K in Q3 2018. 75 funds tracked by Wall St. Rank hold CTIC as of Q4 2018.

  • Wilbanks Smith & Thomas Asset Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q4 2018 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 500 CTI BioPharma Corp. (DE) Common Stock shares in Q4 2018, an estimated $1K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q3 2018 and held it in 1 quarter.
  • Wilbanks Smith & Thomas Asset Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $1K in Q3 2018.
  • 75 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.